FDA experts recommend changes to flu vaccines
Kittisak Kaewchalun /iStock via Getty Images

A group of independent advisors to the FDA has recommended what strains should be included in flu vaccines in an immunization drive for the southern hemisphere in 2024.
The FDAâs Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted unanimously that trivalent flu vaccines should contain influenza A/Victoria/4897/2022 (H1N1)pdm09-like virus; A/Thailand/8/2022 (H3N2)-like virus; and B/Austria/1359417/2021 (B/Victoria lineage)-like virus.

They also unanimously voted for quadrivalent shots to include the above three strains in trivalent vaccines plus the B/Phuket/3073/2013 (B/Yamagata lineage)-like virus as the second influenza B strain in the vaccine.
Flu vaccine makers include GSK (NYSE:GSK), Sanofi (SNY), CSL Limited (OTCQX:CSLLY), and AstraZeneca (AZN).


More on GSK

GSK: Strong Positioning And Trading At Historical Discount
Merck Vs. GSK: The Game-Changer Race In Pharma Excellence
GSK plc (GSK) BofA Global Healthcare Conference (Transcript)
GSK to trim Haleon stake in over $1B share sale
Scynexis hit by FDA clinical hold on antifungal trials